Gilead to focus on early development pipeline with consideration for later-stage deals

Gilead is still hunting for deals, particularly in virology, oncology and inflammation.

During Tuesday’s fourth-quarter earnings call, CEO Daniel O’Day said M&A decisions will be “driven by the science,” with a focus on building up the company’s “late research, early development pipeline.” He added that the company will consider later-stage…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks